Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 25

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 25
---
 our current or future product candidates, which 
 may differ between the United States and other countries or regions;                                              |

| • |     | the costs, timing, and outcome of regulatory review of any of our current or future product candidates; |

| • |     | the costs associated with acquiring or licensing additional product candidates, technologies, or assets,                              
 including the timing and amount of any milestones, royalties, or other payments due in connection with our acquisitions and licenses; |

| • |     | the cost of manufacturing clinical and commercial supplies and any other activities related thereto of our 
 current or future product candidates;                                                                      |

| • |     | the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our                                                                               
 intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; |

| • |     | our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the                                               
 financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; |

| • |     | the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and 
 distribution, for any product candidate for which we receive marketing approval;                            |

| • |     | the revenue, if any, received from commercial sales of the product candidate(s) for which we receive marketing 
 approval;                                                                                                      |

| • |     | expenses to attract, hire, and retain skilled personnel for us to grow as an organization and achieve our 
 business objectives;                                                                                      |

| • |     | the costs of operating as a public company; |

| • |     | our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate 
 reimbursement from third-party and government payors for any products that receive marketing approval;         |

| • |     | our ability to mitigate the impact of adverse macroeconomic conditions or geopolitical events, including any                                                                                                                                     
 health epidemics and their residual effects, the ongoing conflicts between Ukraine and Russia and between Israel and Hamas, bank failures, or inflation and increased interest rates, on our preclinical and clinical development or operations; |

| • |     | the effect of competing technological and market developments; and |

| • |     | the extent to which we acquire or invest in businesses, products, and technologies. |

We will require substantial additional capital in addition to the proceeds of this offering to achieve